1. ALLA AKTIER
  2. NYHETER
  3. BIO-WORKS TECHNOLOGIES

Bio-Works Technologies

Nyheter Bio-Works Technologies Nyheter alla bolag

Bio-Works secures 0.8 MSEK order for gene therapy manufacturing

MAR

Bio-Works has confirmed a new order for a customized, prepacked solution worth 0.8 MSEK to be used in a viral vector manufacturing process. The initial order is for process validation runs, and the potential annual revenue from the project is estimated to be between 3-12 MSEK.

The customer is an American contract manufacturer of gene therapy products.

“I am happy to see that our focus on customized solutions is paying off,” said Jonathan Royce, CEO at Bio-Works. “Bio-Works is providing solutions to biotech companies that other suppliers cannot offer, and we are making good progress to securing our position as the tailor of biomolecule purification.”

The order is confirmed for delivery in Q1 2024.

Contacts
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Jonathan Royce, CEO, e-mail: jonathan.royce@bio-works.com, phone: +46 70 1434143.

About Bio-Works
Bio-Works enables scientists to achieve their purification goals, from laboratory research to large scale bioprocess production. Our vision is a biotech industry that embraces, develops and builds on new methods and novel ideas. WorkBeads™, Bio-Works’ next-generation, agarose-based products, are used to purify proteins, peptides and other biomolecules, resulting in purer therapies and safer diagnostics. Through collaboration with customers and partners, we develop purification solutions that make important medicines available and accessible to everyone.

Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Nasdaq First North (“BIOWKS”), and FNCA Sweden AB, +46 (0) 8-528 00 399, info@fnca.se, is appointed Certified Adviser. For more information, www.bio-works.com.

This information is information that Bio-Works Technologies is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-10-25 08:20 CEST.

Attachments
Bio-Works secures 0.8 MSEK order for gene therapy manufacturing

Datum 2023-10-25, kl 08:20
Källa MFN
Bifogade filer
Bio-Works secures 0.8 MSEK order for gene therapy manufacturing
Affiliate
Kopiera toppinvesterare! Med eToros innovativa CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för att använda CopyTrader-funktionen.
Copy Trading innebär inte investeringsråd. Värdet på dina investeringar kan gå upp eller ned. Ditt kapital löper risk.